Summary

In patients with advanced nonsquamous non-small cell lung cancer (NSCLC), first-line treatment with pemetrexed plus carboplatin (PemC) followed by maintenance Pem is not associated with superior progression-free survival without Grade 4 toxicities compared with treatment with paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab. This article discusses the results of the Study of Patients With Advanced Non-Small Cell Lung Cancer [PRONOUNCE; NCT0948675; Zinner R et al. J Clin Oncol 2013 (suppl; abstr LBA8003)], a randomized, open-label, Phase 3 study that assessed the superiority of 2-drug regimen PemC compared with 3-drug regimen PCB in patients with advanced NSCLC.